Ghiath M. Sukhtian bought $2.5M of OTLK
director, owner at Outlook Therapeutics, Inc.. 2,525,252 shares at an average of $0.99, traded Aug 12, 2026, filed Aug 14, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.5M at market
- +3Relative to holdingsHoldings up 11%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000899140-26-000894, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | POpen-market purchase Common Stockindirect: See footnote | +2,525,252 | $0.99 | $2.5M | 24,617,320 | Aug 14, 2026 |
| Aug 12, 2026 | POpen-market purchase Warrants (right to buy)derivativeindirect: See footnote | +2,525,252 | $0.00 | $0 | 2,525,252 | Aug 14, 2026 |
Related signals
Other insiders at Outlook Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | Outlook Therapeutics, Inc. | Faisal Ghiath Sukhtian director | $100k 95,398 shares | +76% | |
| 45Moderate | Outlook Therapeutics, Inc. | Yezan Munther Haddadin director | $24k 29,000 shares | +78% | |
| 65Notable | Outlook Therapeutics, Inc. | Ghiath M. Sukhtian director, owner | $5.0M 8,539,709 shares | +63% | |
| 52Moderate | Outlook Therapeutics, Inc. | Kurt J Hilzinger director | $177k 400,000 shares | +1691% | |
| 40Moderate | Outlook Therapeutics, Inc. | Yezan Munther Haddadin director | $15k 34,000 shares | +1074% | |
| 40Moderate | Outlook Therapeutics, Inc. | Randy H Thurman director | $2,145 5,000 shares | +843% | |
| 47Moderate | Outlook Therapeutics, Inc. | Faisal Ghiath Sukhtian director | $50k 122,174 shares | +3593% | |
| 45Moderate | OTLKbuy Outlook Therapeutics, Inc. | Lawrence A Kenyon Chief Financial Officer | $28k 5,000 shares | +529% | |
| 33Weak | OTLKbuy Outlook Therapeutics, Inc. | Yezan Munther Haddadin director | $22k 1,882 shares | +59% | |
| 31Weak | OTLKbuy Outlook Therapeutics, Inc. | Jeff Evanson CHIEF COMMERCIAL OFFICER | $26k 62,484 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.